Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (32)

2024

  1. Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis

    Kidney International, Vol. 105, Núm. 1, pp. 177-188

  2. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports

2023

  1. Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

    Kidney360, Vol. 4, Núm. 5, pp. 659-672

  2. Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis

    Nefrologia, Vol. 43, Núm. 1, pp. 6-47

2022

  1. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies

    Nephrology Dialysis Transplantation, Vol. 37, Núm. 11, pp. 2128-2137

  2. Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

    Clinical Kidney Journal, Vol. 15, Núm. 9, pp. 1737-1746

  3. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 7, pp. 1270-1280

2021

  1. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy

    Journal of the American Society of Nephrology, Vol. 32, Núm. 2

  2. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

    Kidney International Reports, Vol. 6, Núm. 9, pp. 2392-2403

  3. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease

    Clinical Journal of the American Society of Nephrology, Vol. 15, Núm. 9, pp. 1287-1298

  2. Risk factors for non-diabetic renal disease in diabetic patients

    Clinical Kidney Journal, Vol. 13, Núm. 3, pp. 380-388

2019

  1. Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

    Kidney International, Vol. 96, Núm. 4, pp. 995-1004

2018

  1. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome

    Kidney International, Vol. 93, Núm. 2, pp. 450-459

  2. Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement

    Clinical Rheumatology, Vol. 37, Núm. 4, pp. 1065-1074

  3. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

    Kidney International Reports, Vol. 3, Núm. 1, pp. 122-132

2017

  1. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain

    BioDrugs, Vol. 31, Núm. 3, pp. 239-249

2016

  1. Efectos pleiotrópicos del paricalcitol, más allá del metabolismo óseo-mineral

    Nefrologia

2015

  1. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document

    Nefrologia

  2. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes

    The Lancet Diabetes and Endocrinology